TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
SAN DIEGO, Nov. 14, 2016 -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”), a three-dimensional biology company focused on delivering scientific and medical breakthroughs using its 3D bioprinting technology, today announced that Chairman and Chief Executive Officer Keith Murphy is scheduled to speak at the 2016 Canaccord Genuity Medical Technologies & Diagnostics Forum in New York on Thursday, November 17th at 1:00 p.m. Eastern Time (ET). The presentation will be simultaneously audio webcast at http://www.organovo.com. The audio webcast will be archived for 90 days following the conference.
About Organovo Holdings, Inc.
Organovo designs and creates functional, three-dimensional human tissues for use in medical research and therapeutic applications. The Company develops 3D human tissue models through internal development and in collaboration with pharmaceutical, academic and other partners. Organovo's 3D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost. The Company’s ExVive Human Liver and Kidney Tissues are used in toxicology and other preclinical drug testing. The Company also actively conducts early research on specific tissues for therapeutic use in direct surgical applications. In addition to numerous scientific publications, the Company’s technology has been featured in The Wall Street Journal, Time Magazine, The Economist, Forbes, and numerous other media outlets. Organovo is changing the shape of life science research and transforming medical care. Learn more at www.organovo.com.
Investor Contact: Steve Kunszabo Organovo Holdings, Inc. +1 (858) 224-1092 [email protected] Press Contact: Jessica Yingling Little Dog Communications +1 (858) 480-2411 [email protected]
